Skip to search formSkip to main contentSkip to account menu

E 1020

Known as: E-1020 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

olprinone

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1997
1997
Beneficial effects of a Ca2+ sensitizer, MCI-154, on the myocardial oxygen consumption-cardiac output relation in patients with left ventricular dysfunction after myocardial infarction: comparison…
1994
1994
Positive inotropism and myocardial energetics: influence of beta receptor agonist stimulation, phosphodiesterase inhibition, and ouabain.
OBJECTIVE The aim was to study the effect of three positive inotropic interventions on myocardial force development and heat… 
1993
1993
Comparison of the effects on arterial-ventricular coupling between phosphodiesterase inhibitor and dobutamine in the diseases human heart.
1993
1993
Ca2+(-)dependent and Ca2+(-)independent vasorelaxation induced by cardiotonic phosphodiesterase inhibitors.
1991
1991
Hemodynamic efficacy of E-1020 in comparison with dopamine on acute mitral regurgitation in anesthetized dogs.
To evaluate the effects of a new phosphodiesterase inhibitor, E-1020 (1, 2-dihydro-6-methyl-2-oxo-5-(imidazo [1, 2-a] pyridin-6… 
1991
1991
Mechanics of contraction and relaxation of the ventricle in experimental heart failure produced by rapid ventricular pacing in the conscious dog.
A model of heart failure produced by rapid ventricular pacing in the conscious dog instrumented with a conductance catheter to… 
1990
1990
Effects of a new cardiotonic agent 1,2-dihydro-6-methyl-2-oxo-5-[imidazo (1,2-a) pyridin-6-yl]-3-pyridine carbonitrile hydrochloride monohydrate (E-1020) on contractile force and cyclic AMP…
E-1020, a newly synthesized imidazopyridinylpyridine or imidazopyridine derivative (structurally closely related to the… 
1990
1990
A Phase I Study of E-1020
A phase I study of E-1020, a newly synthesized selective phosphodiesterase inhibitor that possesses both positive inotropic and… 
1989
1989
Cardiovascular effects of the new cardiotonic agent 1,2-dihydro-6-methyl-2-oxo-5-(imidazo[1,2-a]pyridin-6-yl)-3-pyridine carbonitrile hydrochloride monohydrate. 2nd communication: studies in dogs.
The cardiovascular effects of 1,2-dihydro-6-methyl-2-oxo-5-(imidazo[1,2-a]pyridin-6-yl)-3-pyridine carbonitrile hydrochloride… 
1989
1989
Cardiovascular effects of the new cardiotonic agent 1,2-dihydro-6-methyl-2-oxo-5-(imidazo[1,2-a]pyridin-6-yl)-3-pyridine carbonitrile hydrochloride monohydrate. 1st communication: studies on isolated…
Cardiotonic effects and the mechanism of action of 1,2-dihydro-6-methyl-2-oxo-5-(imidazo[1,2-a]pyridin-6-yl)-3-pyridine… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)